On Monday, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) opened lower -6.50% from the last session, before settling in for the closing price of $7.38. Price fluctuations for CRVS have ranged from $1.30 to $10.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -65.36% at the time writing. With a float of $50.33 million, this company’s outstanding shares have now reached $62.58 million.
In an organization with 28 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 70.73%, operating margin of -10200.81%, and the pretax margin is -23102.85%.
Corvus Pharmaceuticals Inc (CRVS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Corvus Pharmaceuticals Inc is 21.68%, while institutional ownership is 28.59%. The most recent insider transaction that took place on May 06 ’24, was worth 34,624. In this transaction an insider of this company bought 20,000 shares at a rate of $1.73, taking the stock ownership to the 153,773 shares. Before that another transaction happened on May 06 ’24, when Company’s President and CEO bought 577,634 for $1.73, making the entire transaction worth $1,000,000. This insider now owns 577,634 shares in total.
Corvus Pharmaceuticals Inc (CRVS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -65.36% per share during the next fiscal year.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
Check out the current performance indicators for Corvus Pharmaceuticals Inc (CRVS). In the past quarter, the stock posted a quick ratio of 0.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.06 million. That was better than the volume of 0.4 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.12%. Additionally, its Average True Range was 0.59.
During the past 100 days, Corvus Pharmaceuticals Inc’s (CRVS) raw stochastic average was set at 59.74%, which indicates a significant increase from 0.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.58% in the past 14 days, which was lower than the 85.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.08, while its 200-day Moving Average is $4.05. However, in the short run, Corvus Pharmaceuticals Inc’s stock first resistance to watch stands at $7.24. Second resistance stands at $7.58. The third major resistance level sits at $7.76. If the price goes on to break the first support level at $6.72, it is likely to go to the next support level at $6.54. Assuming the price breaks the second support level, the third support level stands at $6.20.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Key Stats
There are currently 64,257K shares outstanding in the company with a market cap of 404.97 million. Presently, the company’s annual sales total 0 K according to its annual income of -27,030 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -40,220 K.
